CON: Anticoagulation for Portal Vein Thrombosis in Advanced Cirrhosis
Kevin M. Rank, John Lake – 2 October 2018
Down‐regulation of TROP‐2 Predicts Poor Prognosis of Hepatocellular Carcinoma Patients
Sarah T. K. Sin, Yan Li, Ming Liu, Yun‐Fei Yuan, Stephanie Ma, Xin‐Yuan Guan – 2 October 2018 – Hepatocellular carcinoma (HCC) is one of the most common and lethal cancer types worldwide, especially in Asian countries. Genetic alterations, including hyperactivation of oncogenes and loss of expression of tumor suppressor genes, greatly contribute to the initiation and progression of HCC. Here we report that down‐regulation of trophoblast cell surface antigen 2 (TROP‐2) was frequently detected in HCC.
Risk of Nonsteroidal Anti‐inflammatory Drugs and Safety of Acetaminophen in Patients with Advanced Liver Disease
Miguel H. Malespin – 2 October 2018
PRO: Patients With Advanced Cirrhosis and Portal Vein Thrombosis Should Receive Anticoagulation
Uyen Kim To, Guadalupe Garcia‐Tsao – 2 October 2018
CON: Anticoagulation for Portal Vein Thrombosis in Advanced Cirrhosis
Kevin M. Rank, John Lake – 2 October 2018
Paracentesis Model for Junior Doctors
Jemma Mildon, Johann Willers, Sam J. Thomson – 2 October 2018
PRO: Patients With Advanced Cirrhosis and Portal Vein Thrombosis Should Receive Anticoagulation
Uyen Kim To, Guadalupe Garcia‐Tsao – 2 October 2018
Evaluating Women’s Preferences for Hepatitis C Treatment During Pregnancy
Tatyana Kushner, Jennifer Cohen, Phyllis C. Tien, Norah A. Terrault – 1 October 2018 – There is a rising prevalence of hepatitis C (HCV) among women of child‐bearing age nationally, which prompted a recommendation by national guidelines to screen all women for HCV during pregnancy. Women with HCV during pregnancy are at risk of perinatal transmission of HCV. Directly acting antiviral (DAA) therapy during pregnancy can potentially reduce the risk of perinatal transmission as well as cure women while they are engaged in antenatal care.
Issue Information
1 October 2018